FibroGen Statistics
Total Valuation
FibroGen has a market cap or net worth of $32.97 million. The enterprise value is -$65.13 million.
Important Dates
The last earnings date was Monday, November 10, 2025, after market close.
| Earnings Date | Nov 10, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
FibroGen has 4.05 million shares outstanding. The number of shares has increased by 1.55% in one year.
| Current Share Class | 4.05M |
| Shares Outstanding | 4.05M |
| Shares Change (YoY) | +1.55% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 2.06% |
| Owned by Institutions (%) | 16.35% |
| Float | 3.58M |
Valuation Ratios
The trailing PE ratio is 0.15.
| PE Ratio | 0.15 |
| Forward PE | n/a |
| PS Ratio | 4.02 |
| Forward PS | 5.28 |
| PB Ratio | 1.91 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.71, with a Debt / Equity ratio of 1.11.
| Current Ratio | 3.71 |
| Quick Ratio | 3.56 |
| Debt / Equity | 1.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.91 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -18.42% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -58.55% |
| Revenue Per Employee | $36,880 |
| Profits Per Employee | $958,462 |
| Employee Count | 225 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 2.78 |
Taxes
| Income Tax | -88,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.53% in the last 52 weeks. The beta is 0.75, so FibroGen's price volatility has been lower than the market average.
| Beta (5Y) | 0.75 |
| 52-Week Price Change | -20.53% |
| 50-Day Moving Average | 10.35 |
| 200-Day Moving Average | 9.07 |
| Relative Strength Index (RSI) | 30.60 |
| Average Volume (20 Days) | 40,818 |
Short Selling Information
The latest short interest is 146,531, so 3.62% of the outstanding shares have been sold short.
| Short Interest | 146,531 |
| Short Previous Month | 104,776 |
| Short % of Shares Out | 3.62% |
| Short % of Float | 4.09% |
| Short Ratio (days to cover) | 4.90 |
Income Statement
In the last 12 months, FibroGen had revenue of $8.30 million and earned $215.65 million in profits. Earnings per share was $53.38.
| Revenue | 8.30M |
| Gross Profit | -30.35M |
| Operating Income | -59.16M |
| Pretax Income | -52.35M |
| Net Income | 215.65M |
| EBITDA | -58.06M |
| EBIT | -59.16M |
| Earnings Per Share (EPS) | $53.38 |
Full Income StatementBalance Sheet
The company has $117.98 million in cash and $19.47 million in debt, giving a net cash position of $98.50 million or $24.35 per share.
| Cash & Cash Equivalents | 117.98M |
| Total Debt | 19.47M |
| Net Cash | 98.50M |
| Net Cash Per Share | $24.35 |
| Equity (Book Value) | 17.49M |
| Book Value Per Share | -4.21 |
| Working Capital | 97.45M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$16.91 million and capital expenditures -$179,000, giving a free cash flow of -$17.09 million.
| Operating Cash Flow | -16.91M |
| Capital Expenditures | -179,000 |
| Free Cash Flow | -17.09M |
| FCF Per Share | -$4.22 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -712.89% |
| Pretax Margin | -630.84% |
| Profit Margin | 2,598.87% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FibroGen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.55% |
| Shareholder Yield | -1.55% |
| Earnings Yield | 646.16% |
| FCF Yield | -51.21% |
Analyst Forecast
The average price target for FibroGen is $146.50, which is 1,697.55% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $146.50 |
| Price Target Difference | 1,697.55% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | -32.03% |
| EPS Growth Forecast (5Y) | -12.25% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 17, 2025. It was a reverse split with a ratio of 1:25.
| Last Split Date | Jun 17, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
FibroGen has an Altman Z-Score of -17.61 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -17.61 |
| Piotroski F-Score | 3 |
